Market Overview

Insys Accepts Founder Kapoor's Resignation, Preps $150 Million To Settle Dept. Of Justice Investigation

Share:
Insys Accepts Founder Kapoor's Resignation, Preps $150 Million To Settle Dept. Of Justice Investigation
Related INSY
25 Stocks Moving In Thursday's Pre-Market Session
Mid-Day Market Update: Trex Rises After Strong Q3 Results; Under Armour Shares Slide

Shares of Insys Therapeutics Inc (NASDAQ: INSY) plummeted as low as $4.10 Tuesday morning as the company faces a notable legal battle concerning its founder John Kapoor.

Kapoor resigned from Insys' board of directors over the weekend after he was arrested last week. The executive is said to have been involved in a scheme in which he allegedly bribed doctors to prescribe patients with a fentanyl-based cancer pain drug.

Kapoor's alleged crime comes at a time when the Trump administration is looking to tackle the concerning opioid epidemic.

"I am confident that I have committed no crimes and believe I will be fully vindicated after trial," Fortune quoted Kapoor as saying in a statement on Sunday.

Another board member, Patrick Fourteau, also resigned due to "personal reasons."

Insys said in a regulatory filing it has set aside $150 million in connection with the Department of Justice investigation, which "represents the Company's best estimate of the minimum liability exposure the Company expects to pay over five years in connection with this matter."

The Department of Justice has not accepted Insys' offer and there are no assurances that "future discussions with the government to resolve these matters will be successful," the company also said.

INsys traded around $5.20 at time of publication, down 9.2 percent.

Related Links:

A Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trump's Opioid Declaration

22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency

Posted-In: Fentanyl John Kapoor OpioidNews Legal Management Movers Trading Ideas Best of Benzinga

 

Related Articles (INSY)

View Comments and Join the Discussion!

Partner Center